<DOC>
	<DOCNO>NCT01831739</DOCNO>
	<brief_summary>This project design address follow hypothesis : Distinct pattern lung microbiome characteristic sarcoidosis phenotype reflect change systemic inflammatory response measure peripheral change gene transcription . The Specific Aims : 1 . To identify peripheral blood mononuclear cell ( PBMC ) gene expression pattern characterize distinct sarcoidosis phenotype . 2 . To determine whether pattern lung microbiome associate sarcoidosis severity disease phenotypes 3 . To correlate mRNA microRNA expression pattern sarcoidosis affect organ change microbiome , clinical parameter PBMC gene expression pattern 4 . To integrate clinical , transcriptomic , microbiome data identify novel molecular phenotype sarcoidosis .</brief_summary>
	<brief_title>Genomic Research Sarcoidosis</brief_title>
	<detailed_description>Sarcoidosis systemic disease characterize formation granulomatous lesion , especially lung , liver , skin , lymph node , heterogeneous set clinical manifestation variable course 1 . Despite significant progress understanding genetic predisposition role immunity , still challenge explain clinical presentation sarcoidosis . Standard clinical assessment , imaging , pulmonary function test ( PFTs ) allow prediction disease course response therapy . Furthermore , good long-term therapy . Considering interaction potential infection , change systemic inflammation , pattern lung microbiome different distinct disease phenotype sarcoidosis well understood , Sarcoidosis protocol Genomic Research AAT Deficiency Sarcoidosis ( GRADS ) grant ( hereafter call GRADS Sarcoidosis protocol ) design address follow : Hypothesis Distinct pattern lung microbiome characteristic sarcoidosis phenotype reflect change systemic inflammatory response measure peripheral change gene transcription . Specific Aims 1 . To identify peripheral blood mononuclear cell ( PBMC ) gene expression pattern characterize distinct sarcoidosis phenotype . 2 . To determine whether pattern lung microbiome associate sarcoidosis severity disease phenotypes 3 . To correlate mRNA microRNA expression pattern sarcoidosis affect organ change microbiome , clinical parameter PBMC gene expression pattern 4 . To integrate clinical , transcriptomic , microbiome data identify novel molecular phenotype sarcoidosis . Focusing accessible PBMCs enable GRADS researcher identify marker disease phenotype , severity , outcome . Analysis lesional transcriptomes ( mRNA , microRNA lincRNA ) add mechanistic insight . High throughput unbiased analysis lung microbiome potentially identify pattern lung microbiome determine disease activity persistence , well response therapy . Participants assign provisional clinical phenotype upon obtain consent time enrollment respective recruiting center . Clinical phenotype review , confirm , monitored ensure achievement study objective . Participants assign clinical phenotype initial study visit exclude additional study participation .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<criteria>1 . Age age 18 85 . 2 . Have diagnosis sarcoidosis establish consensus criterion ( ATS/ERS ) , confirm either biopsy manifestation consistent acute sarcoidosis ( Löfgren 's syndrome ) absence know diagnosis . OR Have suspect diagnosis sarcoidosis schedule undergo biopsy procedure confirm diagnosis sarcoidosis use consensus criterion ( ATS/ERS ) . 3 . Able tolerate willing undergo study procedure . 4 . Be capable understand study form . 5 . Provide sign informed consent . 1 . History comorbid condition severe enough significantly increase risk base investigator discretion . 2 . Currently active smoker . 3 . Undergoing bronchoscopy ( clinical research ) one following : 1. severe pulmonary impairment ( &lt; 50 % predict FVC , &lt; 1 L FEV1 ; DLco &lt; 40 % predict , rest hypoxemia &lt; 92 % without supplemental oxygen ) 2. comorbid disease would preclude bronchoscopy . 3. hypersensitivity intolerance drug require sedation conscious sedation bronchoscopy . 4 . Known systemic autoimmune disease rheumatoid arthritis , lupus , scleroderma , Sjögrens , etc . 5 . Found alternative interstitial lung disease evaluation and/or screen . 6 . Diagnosis unstable cardiovascular disease include myocardial infarction past 6 week , uncontrolled congestive heart failure , uncontrolled arrhythmia 7 . Use anticoagulation ( patient warfarin clopidogrel exclude , patient aspirin alone study even concurrent use ) 8 . Dementia cognitive dysfunction opinion investigator would prevent participant consent study complete study procedure 9 . NonSarcoidosis pulmonary disease ( e.g. , rheumatoid arthritis , lupus , scleroderma ) , opinion investigator , limit interpretability analysis sarcoidosis pulmonary disease 10 . Primary biliary cirrhosis autoimmune hepatitis 11 . Crohn 's disease 12 . Chronic beryllium disease 13 . Have active bacterial viral infection time screen . 14 . Have active ongoing serious infection , include HIV , HBV HCV 15 . Active tuberculosis take medication tuberculosis 16 . Have history demyelinating disease , lymphoproliferative disease , malignancy presume cured nonmetastatic skin cancer 17 . Have evidence likely malignancy chest xray 18 . Are currently pregnant time screen 19 . Currently institutionalize ( e.g. , prison , longterm care facility ) 20 . Hypersensitivity intolerance albuterol sulfate propellant excipients inhaler 21 . History Lung volume reduction surgery , lung resection bronchoscopic lung volume reduction form . 22 . History lung organ transplant 23 . Unable comprehend consent document and/or questionnaires Conditional Exclusions : 1 . Participants present upper respiratory infection pulmonary exacerbation , either solely participantidentified clinically treat , last four week rescreened study fourweek window close . 2 . Participants present current use acute antibiotic acute antibiotic within past four week rescreened study ≥28 day discontinue acute antibiotic . 3 . Female participant present &lt; 3 month give birth ask reschedule visit three month pass since birth . 4 . Former smoker quit &lt; 3months prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Genomics</keyword>
	<keyword>Microbiome</keyword>
	<keyword>Microflora</keyword>
	<keyword>Virome</keyword>
</DOC>